CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00001171
NCT00001171N/ACompleted

Evaluation of Biological, Immunological and Therapeutic Parameters in Brain Tumor Patients

National Institute of Neurological Disorders and Stroke (NINDS)·observational·Posted Nov 4, 1999·Updated Mar 4, 2008

In Brief

An observational study for Brain Neoplasm and 3 related conditions. Completed, across 1 site.

Detailed Summary

Presently, patients with primary malignant brain tumors have a life expectancy of 15 weeks following surgery unless they receive additional types of therapy (chemotherapy, radiotherapy, and/or immunotherapy). Patients that receive additional therapy can increase life expectancy to 50 weeks. The statistics on the life expectancy and survival have increased efforts among researchers to develop new treatments for primary malignant brain tumors. This research project involves the growth and study of human brain tumor cells outside the body in the laboratory as part of an attempt to better understand these tumors and to develop more effective treatments for them.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
1979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 4, 1999
Enrollment StartJul 1, 1979
Study CompletionSep 1, 2005
TodayJul 2, 2026
Posted 26.7 years ago